Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

Vinay Manu Daryani, PharmD, Shringi Sharma, PhD, Guan Xing, PhD, Jeffrey Silverman, PhD, Adeboye Henry Adewoye, MD, Anita Mathias, PhD

Blood (2017) 130 (Supplement 1): 5344.

https://doi.org/10.1182/blood.V130.Suppl_1.5344.5344

Published: 2017

Journal Articles

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH

Anita Hill, Anna Gaya Valls, Morag Griffin, Talha Munir, Anna Borodovsky, Nori Kawahata, Helen Mclean, Kelvin Shi, Angela M. Partisano, Jae Kim, Nader Najafian, Alvaro Urbano

Blood (2016) 128 (22): 3891.

https://doi.org/10.1182/blood.V128.22.3891.3891

Published: 2016

Journal Articles

EphB4/ephrinB2 ephrinB1 Interaction Mediated Chronic Myelogenous Leukemia Mesenchymal Stromal Cells Osteogenic Differentiation in Vitro and In Vivo

Li Lin, MD, Xu Na, PhD, Jiang Zhiwu, Lu Qisi, Zhou Xuan, Lu Ziyuan, Huang Jixian, MD, Li Yuling, He Bolin, Pan Chengyun, Li Peng, Liu Xiaoli, MD

Blood (2016) 128 (22): 1901.

https://doi.org/10.1182/blood.V128.22.1901.1901

Published: 2016

Journal Articles

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Antonio M Risitano, MD PhD, Michael Storek, Leonardo Sahelijo, MD, Mittie Doyle, Yang Dai, Ilene Ceil Weitz, MD, Judith C.W. Marsh, MD, Modupe Elebute, MBChB, MD, Casey L O'Connell, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Giridharan Ramsingh, MD, Serena Marotta, MD, Andrzej Hellmann, Ante S. Lundberg, MD

Blood (2015) 126 (23): 2137.

https://doi.org/10.1182/blood.V126.23.2137.2137

Published: 2015

Journal Articles

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results

Anita Hill, Jorg Taubel, Jim Bush, Anna Borodovsky, Noriyuki Kawahata, Helen Mclean, Christine Powell, Prasoon Chaturvedi, Garvin Warner, Pushkal Garg, Benny Sorensen

Blood (2015) 126 (23): 2413.

https://doi.org/10.1182/blood.V126.23.2413.2413

Published: 2015

Journal Articles

Pharmacokinetics/Pharmacodynamic Relationship in Busulfan Conditioning Regimen: Results from a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation

Blood (2014) 124 (21): 425.

https://doi.org/10.1182/blood.V124.21.425.425

Published: 2014

Journal Articles

Autoimmune Myelofibrosis (AIMF) – Clinical Features, Course and Outcome

Caroline Irene Piatek, M.D., Maria E. Vergara-Lluri, M.D., Vinod Pullarkat, MD, Imran N. Siddiqi, M.D, Ph.D., Casey O'Connell, MD, Donald I. Feinstein, MD, Russell K. Brynes, MD

Blood (2013) 122 (21): 3714.

https://doi.org/10.1182/blood.V122.21.3714.3714

Published: 2013

Journal Articles

TNT009, a Classical Complement Pathway Specific Inhibitor, Prevents Complement Dependent Hemolysis Induced By Cold Agglutinin Disease Patient Autoantibodies

Sandip Panicker, Ph.D., Ju Shi, Ph.D., Eileen Rose, Sami Hussain, Susan Tom, William Strober, Steven R. Sloan, M.D., Ph.D., Graham Parry, Ph.D., Nancy Stagliano, Ph.D.

Blood (2013) 122 (21): 42.

https://doi.org/10.1182/blood.V122.21.42.42

Published: 2013

Journal Articles

Autoimmunity in Patients (pts) with Chronic Myelomonocytic Leukemia (CMML): A Frequent Finding

Amer Swedeh, Mrinal Patnaik, Dima Alfakara, Aneel A Ashrani, Rajiv Pruthi, Michelle Elliott, Mark Litzow, MD, Aref Al-Kali, MD

Blood (2012) 120 (21): 4930.

https://doi.org/10.1182/blood.V120.21.4930.4930

Published: 2012

Journal Articles

Screening for Potential Covariates Influencing the Pharmacokinetics of Intravenous Busulfan: Results From a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation

Zeinab Daher Abdi, Angelo Paci, PharmD, PhD, Despina Moshous, Jean-Hugues Dalle, MD, Nathalie Bleyzac, Benedicte Neven, Claire Galambrun, Véronique Kemmel, Aurélie Pétain, Sophie Broutin, Laurent Nguyen, Gilles Vassal

Blood (2010) 116 (21): 1811.

https://doi.org/10.1182/blood.V116.21.1811.1811

Published: 2010

Journal Articles

CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity

Ronald P Taylor, PhD, Clive S. Zent, MD, Paul V Beum, PhD, Margaret A Lindorfer, PhD, George Weiner, MD

Blood (2010) 116 (21): 3585.

https://doi.org/10.1182/blood.V116.21.3585.3585

Published: 2010

Journal Articles

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

V. Michael Holers, Istvan Mazsaroff, PhD, Hillary Akana, Christopher G. Smith, J. Woodruff Emlen, MD, Russell C. Marians, PhD, Christopher J. Horvath, DVM

Blood (2009) 114 (22): 3021.

https://doi.org/10.1182/blood.V114.22.3021.3021

Published: 2009

Journal Articles

In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs.

Kerstin Jonsson-Videsater, Dina Ali, MD, Hareth Nahi, Sofia Bengtzen, Stefan Deneberg, Christer Paul, Professor, Soren Lehmann, MD, PhD

Blood (2009) 114 (22): 2751.

https://doi.org/10.1182/blood.V114.22.2751.2751

Published: 2009

Journal Articles

Clinical Significance of Cytocentrifuge Preparation Analysis of Low-Cell-Count Cerebrospinal Fluid Specimens.

Guylaine Lajeunesse-Viens, Bernadette Dufault, T.M., Xiaoduan Weng, PhD, Bernard Lemieux, MD, FRCPC, Marie Florescu, MD, FRCPC

Blood (2007) 110 (11): 3872.

https://doi.org/10.1182/blood.V110.11.3872.3872

Published: 2007

NARROW

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH

EphB4/ephrinB2 ephrinB1 Interaction Mediated Chronic Myelogenous Leukemia Mesenchymal Stromal Cells Osteogenic Differentiation in Vitro and In Vivo

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results

Pharmacokinetics/Pharmacodynamic Relationship in Busulfan Conditioning Regimen: Results from a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation

Autoimmune Myelofibrosis (AIMF) – Clinical Features, Course and Outcome

TNT009, a Classical Complement Pathway Specific Inhibitor, Prevents Complement Dependent Hemolysis Induced By Cold Agglutinin Disease Patient Autoantibodies

Autoimmunity in Patients (pts) with Chronic Myelomonocytic Leukemia (CMML): A Frequent Finding

Screening for Potential Covariates Influencing the Pharmacokinetics of Intravenous Busulfan: Results From a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation

CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs.

Clinical Significance of Cytocentrifuge Preparation Analysis of Low-Cell-Count Cerebrospinal Fluid Specimens.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only